Published in Anticancer Agents Med Chem on July 01, 2011
An introduction to proteoglycans and their localization. J Histochem Cytochem (2012) 1.08
Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2014) 0.82
Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol (2015) 0.75
Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma. Oncotarget (2016) 0.75
Primary colon cancer with a high serum PIVKA-II level. Int J Surg Case Rep (2014) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Global cancer statistics. CA Cancer J Clin (1999) 8.82
Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet (1996) 4.62
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
WNT/beta-catenin signaling in liver health and disease. Hepatology (2007) 3.26
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res (2005) 2.68
Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res (2010) 2.67
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08
Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol (1999) 1.93
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Glypicans in growth control and cancer. Glycobiology (2001) 1.75
Glypican-3 expression is silenced in human breast cancer. Oncogene (2001) 1.74
Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res (1997) 1.67
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer (2003) 1.54
siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia (2007) 1.51
Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50
Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol (2008) 1.49
The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem (2004) 1.47
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res (1999) 1.40
An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene (2005) 1.38
Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol (2003) 1.36
Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer (2010) 1.36
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res (2008) 1.35
Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res (2009) 1.33
Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics (1997) 1.33
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33
Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem (2005) 1.32
Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol (2006) 1.32
Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res (2004) 1.32
Glypican-3: a new target for cancer immunotherapy. Eur J Cancer (2010) 1.30
When Wnts antagonize Wnts. J Cell Biol (2003) 1.29
Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol (1988) 1.28
Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet (1998) 1.26
Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol (2006) 1.26
Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol (2001) 1.26
Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene (2000) 1.21
Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol (2008) 1.20
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun (2008) 1.16
Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol (2006) 1.14
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.09
HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol (2008) 1.04
Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer (2011) 0.99
Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol (2007) 0.99
The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol (2003) 0.96
Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol (2008) 0.96
Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer (2007) 0.92
Loss of glypican-3 function causes growth factor-dependent defects in cardiac and coronary vascular development. Dev Biol (2009) 0.90
Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages. Cancer Biol Ther (2009) 0.86
Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel. Diagn Cytopathol (2009) 0.85
Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. Mol Cells (2006) 0.80
Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol Rep (2009) 0.79
Mapping of the Simpson-Golabi-Behmel overgrowth syndrome gene (GPC3) to chromosome X in human and rat by fluorescence in situ hybridization. Mamm Genome (1997) 0.79
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res (2005) 2.68
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell (2008) 1.94
The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem (2004) 1.47
Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochem J (2008) 1.37
Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer (2010) 1.36
The role of glypicans in mammalian development. Biochim Biophys Acta (2002) 1.33
Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem (2005) 1.32
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol (2011) 1.14
Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand. A novel mechanism of Anoikis of intestinal epithelial cells. J Biol Chem (2002) 1.08
A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene (2005) 1.07
ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem (2005) 1.07
Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci (2014) 1.03
Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk. Mol Cell Biol (2005) 1.02
Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst (2007) 0.97
Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat (2008) 0.97
Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo. Mech Dev (2005) 0.96
The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol (2003) 0.96
Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells. Oncogene (2002) 0.95
Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol (2008) 0.94
Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res (2005) 0.94
Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian hedgehog. EMBO Rep (2009) 0.90
LRP1 mediates Hedgehog-induced endocytosis of the GPC3-Hedgehog complex. J Cell Sci (2012) 0.86
Regulation of bone morphogenetic protein signalling and cranial osteogenesis by Gpc1 and Gpc3. Bone (2013) 0.84
Immunohistochemical study of glypican 3 in thyroid cancer. Oncology (2008) 0.84
Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest (2002) 0.79
A patient with the Simpson-Golabi-Behmel syndrome displays a loss-of-function point mutation in GPC3 that inhibits the attachment of this proteoglycan to the cell surface. Am J Med Genet A (2009) 0.77